Navigating the Nasal–Brain Nexus: Intranasal Delivery of Therapeutics for Brain Tumors – from Direct Nose-to-Brain Transport to Multidimensional Antitumor Mechanisms
- 1Department of Neurosurgery
- 2Cancer Research Center
Abstract
Ruijun Wang,1 Rile Ge,2 Zhiqi Li,3 Yuanming Pan,3 Zhanbiao He1 1Department of Neurosurgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People’s Republic of China; 2Graduate School, Inner Mongolia Medical College, Hohhot, Inner Mongolia, People’s Republic of China; 3Cancer Research Center, Beijing Chest Hospital, Capital Medical University and Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People’s Republic of ChinaCorrespondence: Yuanming Pan, Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China, Tel/Fax +86-10-89509372, Email [email protected] Zhanbiao He, Department of Neurosurgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, 010050, People’s Republic of China, Email [email protected]: Intranasal drug delivery represents a non-invasive, brain-targeted therapeutic strategy that bypasses the blood-brain barrier primarily through the olfactory and trigeminal nerve pathways, enabling efficient therapeutic entry into the central nervous system for brain tumor treatment. This review systematically examines the anatomical foundations, pharmacokinetic profiles, and therapeutic applications of this route in glioblastoma (GB), medulloblastoma, and meningioma. Based on nasal mucosal physiology, delivery systems are classified into solutions, gels, particulate carriers, and nanovesicles. Their design must match mucus thickness, mucociliary clearance, and target expression to achieve prolonged retention and precise delivery. Material selection—including natural/synthetic polymers, lipids, and biomimetic membranes—offers distinct advantages; physicochemical parameters such as size, surface charge, and deacetylation degree critically influence mucus penetration, cellular uptake, and biocompatibility. Intranasal delivery significantly increases brain drug concentration and tumor targeting index, prolonging survival in animal models. It exerts multidimensional antitumor effects by modulating neurotransmitters, reshaping neuroinflammation, regulating neuronal plasticity and circuits, influencing the gut–microbiota–brain axis, and intervening in epigenetic mechanisms. Preliminary clinical trials confirm safety and potential efficacy, but challenges remain: dose limitations, inter-individual variability, formulation stability, and unclear regulatory pathways. Future research should focus on smart responsive systems, nasal–brain tumor pharmacokinetic/pharmacodynamic models, and patient-specific 3D-printed nasal models to enhance diagnostic–therapeutic integration. Combining in situ imaging, cross-species physiological databases, and standardized guidelines may accelerate clinical translation, positioning intranasal delivery as a key component of comprehensive brain tumor therapy.Graphical Abstract: A) Strengths quadrant with heading, Strengths and five labeled points with medical icons. S1, BBB bypass. Olfactory and trigeminal routes. Brain concentration: 2.5 to 5 times IV. S2, Rapid absorption. T max: 15 to 30 min asterisk. S3, Brain-directed exposure. Brain AUC: 10.5 times IV asterisk. Plasma AUC: 10 to 33 percent of IV. S4, Noninvasive administration. Potential for trained self-administration. S5, Avoidance of hepatic first pass. For directly absorbed fractions. Icons show a nasal cavity and brain, a nasal tissue cross section, a blood vessel cross section, a clock, a person using a nasal spray and a liver with gastrointestinal tract. B) Weaknesses quadrant with heading, Weaknesses and five labeled points with nasal and formulation icons. W1, Limited dose volume. Human volume: 100 to 200 micro liter per nostril asterisk. W2, Anatomical variability. Interindividual AUC CV: 30 to 50 percent. W3, Mucociliary clearance. Clearance half-time: 15 to 20 min asterisk. W4, Enzymatic degradation. Peptides and proteins are vulnerable. W5, Formulation instability. Aggregation, leakage and activity loss. Icons include a nasal spray directed into a nasal cavity, multiple nasal cavity cross sections indicating variability, a mucosal surface with particles above it and molecular and particle clusters. C) Opportunities quadrant with heading, Opportunities and five labeled points with therapy, imaging, modeling and device icons. O1, Combination therapy. Radiotherapy plus immunotherapy. Example MST: 28 to 70 days asterisk. O2, Theranostic platforms. MRI slash fluorescence plus drug delivery. O3, Personalized 3D nasal models. Deposition prediction accuracy greater than 85 percent asterisk. O4, Smart-responsive carriers. pH slash ROS slash enzyme-triggered release. O5, CFD-optimized devices. Spray size, angle and airflow. Icons include a brain with symbols around it, medical scan style images, a nasal model in a rectangular frame, a circular particle with surrounding dots and a nasal spray with airflow paths. D) Threats quadrant with heading, Threats and five labeled points with regulatory, manufacturing, safety, cost and device icons. T1, Regulatory complexity. Product-specific drug-device pathway. T2, GMP scale-up. Batch consistency and sterile production. T3, Long-term safety gaps. Nasal, olfactory and CNS monitoring. T4, Development cost. Manufacturing and trial investment. T5, Device standardization. Performance comparability across devices. Icons include a government building, manufacturing vessels and containers, a nasal tissue strip with a brain and a clock, documents with a chart and coin stacks and multiple nasal spray device shapes.A SWOT infographic on intranasal drug delivery listing strengths, weaknesses, opportunities and threats.Keywords: transnasal administration, brain tumors, brain-targeted delivery, neurotransmitter regulation, epigenetic regulation
Related
- Navigating the Nonylphenol Hazard: Insights into Toxicity Mechanisms and Mitigation Approaches
- Placental Iron Homeostasis: Navigating the Delicate Balance Between Transport and Ferroptosis
- Alzheimer's Disease Neurofibrillary Pathophysiology: PTPRD- and Flavonol-Modified Mechanisms, Prevention and Therapeutics.
- Evolving Mechanisms, Enduring Goals: NICHD OPPTB Support for the Science of Therapeutics in Pregnancy and Childhood (2004–Present)
- Antibody peptide conjugates as multifunctional therapeutics: Mechanisms, challenges, and prospects.
BibTeX
@article{wang2026navigating,
title = {{Navigating the Nasal–Brain Nexus: Intranasal Delivery of Therapeutics for Brain Tumors – from Direct Nose-to-Brain Transport to Multidimensional Antitumor Mechanisms}},
author = {Wang R and Ge R and Li Z and Pan Y and He Z},
journal = {International Journal of Nanomedicine},
year = {2026},
month = nov,
url = {https://www.dovepress.com/navigating-the-nasalbrain-nexus-intranasal-delivery-of-therapeutics-fo-peer-reviewed-fulltext-article-IJN},
note = {CC BY},
}
RIS
TY - JOUR
TI - Navigating the Nasal–Brain Nexus: Intranasal Delivery of Therapeutics for Brain Tumors – from Direct Nose-to-Brain Transport to Multidimensional Antitumor Mechanisms
AU - Wang R
AU - Ge R
AU - Li Z
AU - Pan Y
AU - He Z
PY - 2026
DA - 2026/11/15
JO - International Journal of Nanomedicine
UR - https://www.dovepress.com/navigating-the-nasalbrain-nexus-intranasal-delivery-of-therapeutics-fo-peer-reviewed-fulltext-article-IJN
AB - Ruijun Wang,1 Rile Ge,2 Zhiqi Li,3 Yuanming Pan,3 Zhanbiao He1 1Department of Neurosurgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, People’s Republic of China; 2Graduate School, Inner Mongolia Medical College, Hohhot, Inner Mongolia, People’s Republic of China; 3Cancer Research Center, Beijing Chest Hospital, Capital Medical University and Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People’s Republic of ChinaCorrespondence: Yuanming Pan, Cancer Research Center, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, 101149, People’s Republic of China, Tel/Fax +86-10-89509372, Email [email protected] Zhanbiao He, Department of Neurosurgery, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, 010050, People’s Republic of China, Email [email protected]: Intranasal drug delivery represents a non-invasive, brain-targeted therapeutic strategy that bypasses the blood-brain barrier primarily through the olfactory and trigeminal nerve pathways, enabling efficient therapeutic entry into the central nervous system for brain tumor treatment. This review systematically examines the anatomical foundations, pharmacokinetic profiles, and therapeutic applications of this route in glioblastoma (GB), medulloblastoma, and meningioma. Based on nasal mucosal physiology, delivery systems are classified into solutions, gels, particulate carriers, and nanovesicles. Their design must match mucus thickness, mucociliary clearance, and target expression to achieve prolonged retention and precise delivery. Material selection—including natural/synthetic polymers, lipids, and biomimetic membranes—offers distinct advantages; physicochemical parameters such as size, surface charge, and deacetylation degree critically influence mucus penetration, cellular uptake, and biocompatibility. Intranasal delivery significantly increases brain drug concentration and tumor targeting index, prolonging survival in animal models. It exerts multidimensional antitumor effects by modulating neurotransmitters, reshaping neuroinflammation, regulating neuronal plasticity and circuits, influencing the gut–microbiota–brain axis, and intervening in epigenetic mechanisms. Preliminary clinical trials confirm safety and potential efficacy, but challenges remain: dose limitations, inter-individual variability, formulation stability, and unclear regulatory pathways. Future research should focus on smart responsive systems, nasal–brain tumor pharmacokinetic/pharmacodynamic models, and patient-specific 3D-printed nasal models to enhance diagnostic–therapeutic integration. Combining in situ imaging, cross-species physiological databases, and standardized guidelines may accelerate clinical translation, positioning intranasal delivery as a key component of comprehensive brain tumor therapy.Graphical Abstract: A) Strengths quadrant with heading, Strengths and five labeled points with medical icons. S1, BBB bypass. Olfactory and trigeminal routes. Brain concentration: 2.5 to 5 times IV. S2, Rapid absorption. T max: 15 to 30 min asterisk. S3, Brain-directed exposure. Brain AUC: 10.5 times IV asterisk. Plasma AUC: 10 to 33 percent of IV. S4, Noninvasive administration. Potential for trained self-administration. S5, Avoidance of hepatic first pass. For directly absorbed fractions. Icons show a nasal cavity and brain, a nasal tissue cross section, a blood vessel cross section, a clock, a person using a nasal spray and a liver with gastrointestinal tract. B) Weaknesses quadrant with heading, Weaknesses and five labeled points with nasal and formulation icons. W1, Limited dose volume. Human volume: 100 to 200 micro liter per nostril asterisk. W2, Anatomical variability. Interindividual AUC CV: 30 to 50 percent. W3, Mucociliary clearance. Clearance half-time: 15 to 20 min asterisk. W4, Enzymatic degradation. Peptides and proteins are vulnerable. W5, Formulation instability. Aggregation, leakage and activity loss. Icons include a nasal spray directed into a nasal cavity, multiple nasal cavity cross sections indicating variability, a mucosal surface with particles above it and molecular and particle clusters. C) Opportunities quadrant with heading, Opportunities and five labeled points with therapy, imaging, modeling and device icons. O1, Combination therapy. Radiotherapy plus immunotherapy. Example MST: 28 to 70 days asterisk. O2, Theranostic platforms. MRI slash fluorescence plus drug delivery. O3, Personalized 3D nasal models. Deposition prediction accuracy greater than 85 percent asterisk. O4, Smart-responsive carriers. pH slash ROS slash enzyme-triggered release. O5, CFD-optimized devices. Spray size, angle and airflow. Icons include a brain with symbols around it, medical scan style images, a nasal model in a rectangular frame, a circular particle with surrounding dots and a nasal spray with airflow paths. D) Threats quadrant with heading, Threats and five labeled points with regulatory, manufacturing, safety, cost and device icons. T1, Regulatory complexity. Product-specific drug-device pathway. T2, GMP scale-up. Batch consistency and sterile production. T3, Long-term safety gaps. Nasal, olfactory and CNS monitoring. T4, Development cost. Manufacturing and trial investment. T5, Device standardization. Performance comparability across devices. Icons include a government building, manufacturing vessels and containers, a nasal tissue strip with a brain and a clock, documents with a chart and coin stacks and multiple nasal spray device shapes.A SWOT infographic on intranasal drug delivery listing strengths, weaknesses, opportunities and threats.Keywords: transnasal administration, brain tumors, brain-targeted delivery, neurotransmitter regulation, epigenetic regulation
SN - 1178-2013
ER -